{
    "clinical_study": {
        "@rank": "68809", 
        "brief_summary": {
            "textblock": "The purpose of this study is to provide Sildenafil therapy for subjects who completed\n      A1481156 study and are judged by the investigator to derive clinical benefit from continued\n      treatment with Sildenafil, prior to reimbursement and availability for subjects in the\n      Russian Federation."
        }, 
        "brief_title": "Sildenafil Therapy For Subjects Who Derive Clinical Benefit From Continued Treatment With Sildenafil", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Pulmonary Arterial Hypertension (PAH)", 
        "condition_browse": {
            "mesh_term": [
                "Hypertension, Pulmonary", 
                "Hypertension"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients Who Completed study A1481156 and Are Judged by the Investigator to Derive\n             Clinical Benefit from Continued Treatment with Sildenafil, Prior to Reimbursement and\n             Availability for Subjects in Russian Federation.\n\n          -  Child bearing age women should have apropriate contraception.\n\n          -  Signed informed consent. Patients who have a wish and possibility to follow treatment\n             regimens in terms of the study.\n\n        Exclusion Criteria:\n\n          -  Pregnant and lactating women.\n\n          -  Participation in other studies in the current moment or during study period except of\n             A1481156.\n\n          -  Patients with severe acute or chronic diseases psychiatric disorders or laboratory\n             abnormalities."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "30 Years", 
            "minimum_age": "10 Years"
        }, 
        "firstreceived_date": "July 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01897740", 
            "org_study_id": "A1481307"
        }, 
        "intervention": {
            "description": "tablets of sildenafil 20 mg 3 times a day for subjects with body weight > 20 kg and 10 mg TID for subjects with body weight \u2264 20 kg. If subject is 18 years of age or older, the recommended dose is 20 mg TID, regardless of body weight.", 
            "intervention_name": "sildenafil", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Sildenafil"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "sildenafil", 
            "pulmonary arterial hypertension", 
            "PAH"
        ], 
        "lastchanged_date": "May 14, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A1481307&StudyName=Sildenafil%20Therapy%20For%20Subjects%20Who%20Derive%20Clinical%20Benefit%20from%20Continued%20Treatment%20With%20Sildenafil"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Moscow", 
                    "country": "Russian Federation", 
                    "zip": "125412"
                }, 
                "name": "Moscow research institute of pediatrics and pediatric surgery"
            }
        }, 
        "location_countries": {
            "country": "Russian Federation"
        }, 
        "official_title": "A Local, Single-Centre, Extension, Open Label Access Study, To Provide Sildenafil Therapy for Subjects Who Completed A1481156 Study And Are Judged By The Investigator To Derive Clinical Benefit From Continued Treatment With Sildenafil, Prior To Reimbursement And Availability for Subjects in Russian Federation", 
        "overall_contact": {
            "last_name": "Pfizer CT.gov Call Center", 
            "phone": "1-800-718-1021"
        }, 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Available", 
        "oversight_info": {
            "authority": "Russia: Ministry of Health of the Russian Federation", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01897740"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "N/A", 
        "study_type": "Expanded Access", 
        "verification_date": "May 2014"
    }
}